Vugene secures 1 million euros to revolutionise biological research
- austejalazaraviciu9
- May 6
- 4 min read
Updated: May 7
● Financing led by Superhero Capital backed by NGL Ventures, Coinvest Capital and angel investors
● Building on strong international R&D customer base across biotech, pharma and academia
● Transforming multi-omics data into functional discoveries
● Addressing a potential USD 16 billion market
Vilnius, Lithuania – May 6th 2025 – VUGENE (‘ ‘the Company’), a Lithuania-based multiomics data analysis company, today announced the closing an investment round of 1 million Euros, led by Superhero Capital together with participation from NGL Ventures, Coinvest Capital and angel investors. The Company will now deploy the new funds to accelerate its establishment as a global service-as-a-software company supporting researchers and industry customers worldwide by turning complex multi-omics data into functional discoveries.
VUGENE was founded in 2021 by Juozas Gordevičius with the core mission to bring together
experts in biology, data and computer science to transform and advance health-related
scientific research. The ability of VUGENE’s platform to integrate biological data from all
sources – transcriptomics, (epi)genomics, metabolomics, proteomics involving spatial and
single-cell methods – has rapidly gained it a strong user base in academic research, which
has since expanded into the industry. Among current clients, there are well known world
leading institutions: Corewell Health, Barrow Neurological Institute, Epigenetic Clock
Development Foundation, RUSH University Medical Center, rAAVen Therapeutics, Biocrates.
Gražina Mykolaitytė, CEO and Co-Founder of VUGENE: “This investment serves as a confirmation that our brilliant, high-performing, and highly skilled multidisciplinary team is driving biomedical data science towards outstanding innovation. I’m truly excited that this investment will allow us to scale our innovation globally and empower our team to deliver the most accurate and comprehensive insights, helping R&D companies in the life science and biotech industries achieve their scientific discoveries. I’m incredibly proud of our team and company founder Juozas Gordevicius, for living and sharing his vision with all of us.”
Juozas Gordevičius, Founder of VUGENE, commented: “VUGENE analysis integrates data from multiple omics experiments, providing a comprehensive characterization of biological systems. This enables our customers to discover therapeutic targets, understand disease mechanisms, and develop advanced, more personalized diagnostic solutions. Already we are seeing many of them making exciting discoveries in a wide range of fields - Neurodegeneration, Cancer, Gene Therapy, Microbial Genomics, Cardiovascular disorders. We are therefore delighted to have attracted support from this syndicate of high-quality, experienced investors to fund our continued growth and expansion.”
Viktorija Trimbel, Managing Director at Coinvest Capital: We joined investment round to support experienced founders in they pursuit to provide solutions, enabling fasted data-driven scientific discoveries, as well as to encourage investments by business angels, that benefit from our profit-sharing incentive. The founders stood-out by the track record and we look foward to witness the next stage of VUGENE growth.
Gytenis Galkis, Partner at Superhero Capital, said: "We are proud to lead this competitive investment round in Vugene, a company that's uniquely positioned to make a significant impact in biological research by turning complex multi-omics data into actionable insights. Juozas Gordevičius and Gražina Mykolaitytė embody the visionary spirit and disciplined execution we admire at Superhero Capital, both in their entrepreneurial journey and their shared passion for sailing—an activity that mirrors the precision, teamwork, and resilience they've demonstrated in navigating the competitive waters of biotech innovation. With their strong international R&D foundation and exceptional multidisciplinary team, we believe Vugene is poised to become a global leader in biotech data analytics.”
Justinas Pašys, CEO of NGL Ventures, added: “VUGENE is addressing a fundamental bottleneck in biomedical research by automating complex biological data interpretation. The startup's strong commercial traction, exceptional team, and proprietary technology position them well to continue its growth and become a category leader in a rapidly growing market. We are excited to back VUGENE as they scale their product globally and help accelerate scientific discoveries across biotech and pharma.”
For further information please contact:
VUGENE E: hi@vugene.com
RHA Communications
About VUGENE
VUGENE, founded in 2021, is a Lithuania-based multi-omics data analysis and interpretation company. Being a service-as-a-software company, VUGENE enables characterization of treatment models and improved understanding of disease mechanisms. This allows diagnostic predictors to be developed to identify drug targets and biomarkers that can ultimately lead to the development of novel therapeutics and diagnostics. For more information, visit: www.vugene.com
About Coinvest Capital
Coinvest Capital is an early-stage venture capital fund established by Lithuania’s national development bank ILTE. The fund invests public capital entrusted by the EU and the Republic of Lithuania - together with business angels and other VC funds - into promising European startups that create long-term value for Lithuania. Since its inception, the fund and its partners have co-invested in 44 startups and the total of EUR 45.8 million, of which EUR 20.2 million was the Fund’s contribution. It offers a globally unique profit-sharing model, capping its own annual return at 4–8%, with any profits beyond this threshold allocated to accredited private co-investors. With current dry powder of EUR 17.85 million, Coinvest Capital is well positioned to continue coinvesting across diverse sectors, including AI, life sciences or single-use defence.
For more information visit: www.coinvest.lt
About Superhero Capital
Superhero Capital is an early-stage venture capital firm based in Finland, investing across Finland and the Baltics. With our fourth fund, we continue a strong legacy of empowering visionary entrepreneurs. Our collective partner experience spans investments in over 100 technology-driven companies. We are committed to supporting founders who aspire to build globally impactful businesses from the New Nordics. For more information, visit www.superherocapital.com
About NGL Ventures
NGL Ventures is an angel syndicate company and a startup investor network which in the past 1.5 years has invested EUR 5M in 16 startups with over 200 angel investors. For more information visit: https://www.ngl.vc/
Comments